Patient Registry of Intrathecal Ziconotide Management(PRIZM)

NCT ID: NCT01888120

Last Updated: 2017-03-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study are to evaluate the effectiveness, long-term safety, tolerability, satisfaction with treatment, and health-related quality of life (HRQoL) associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Severe Chronic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Severe Chronic Pain

Ziconotide

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ziconotide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is at least 18 years of age at the time of study entry.
* Patient who has severe chronic pain, whom IT therapy is warranted, and who is intolerant of, or refractory to other treatments, such as systemic analgesics, adjunctive therapies, and/or IT morphine.
* Patient is planned to be initiated on IT PRIALT as the sole agent in the pump at a participated site.
* Patient has not received PRIALT treatment administered continuously via Medtronic SynchroMed® II pump within the past 30 days.
* Patient has a life expectancy \>6 months as determined by the physician.
* Patient is able to read, understand, and voluntarily sign the IRB-approved informed consent document prior to the performance of any study-specific procedures.
* Patient is able to understand and complete required assessments.

Exclusion Criteria

* Patient has a known hypersensitivity to PRIALT or any of its formulation components.
* Patient has a pre-existing history of psychosis.
* Patient has infection at the microinjection site, uncontrolled bleeding diathesis, or known spinal canal obstruction that impairs circulation of cerebrospinal fluid.
* Patient is being initiated with PRIALT in conjunction with other IT agents.
* Patients with any other concomitant treatment or medical condition that, in the opinion of the clinician, would render IT administration hazardous.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jazz Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

I-Zu Huang, MD

Role: STUDY_DIRECTOR

Jazz Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tennessee Valley Pain Consultants

Huntsville, Alabama, United States

Site Status

Valley Pain Specialists

Chandler, Arizona, United States

Site Status

Desert Pain Institute

Mesa, Arizona, United States

Site Status

Valley Pain Specialists

Scottsdale, Arizona, United States

Site Status

White River Health System

Batesville, Arkansas, United States

Site Status

United Pain Care

Sherwood, Arkansas, United States

Site Status

Coastal Pain Research

Carlsbad, California, United States

Site Status

Pain Therapy Solutions

Chino, California, United States

Site Status

Pain Medicine Associates, Inc.

Fountain Valley, California, United States

Site Status

University of California, San Diego

La Jolla, California, United States

Site Status

Napa Pain Institute

Napa, California, United States

Site Status

Cypress Ambulatory Surgery Center

Santa Maria, California, United States

Site Status

Orthopedic Pain Specialists

Santa Monica, California, United States

Site Status

Colorado Pain Clinic

Loveland, Colorado, United States

Site Status

St. Francis Pain Center

Wilmington, Delaware, United States

Site Status

Clearwater Pain Management

Clearwater, Florida, United States

Site Status

Florida Pain Institute

Merritt Island, Florida, United States

Site Status

AMPM Research Clinic

Miami, Florida, United States

Site Status

Kennedy-White Orthopaedic Center

Sarasota, Florida, United States

Site Status

JM Clinical Research

South Miami, Florida, United States

Site Status

Tallahassee Neurological Clinic

Tallahassee, Florida, United States

Site Status

Shepherd Center, Inc

Atlanta, Georgia, United States

Site Status

Exodus Pain Clinic

Boise, Idaho, United States

Site Status

Thompson and Chou Center for PM&R

Louisville, Kentucky, United States

Site Status

Ana Pain Management

Clinton Township, Michigan, United States

Site Status

Kozmary Center for Pain Management

Las Vegas, Nevada, United States

Site Status

Spinal & Skeletal Pain Medicine

Utica, New York, United States

Site Status

The Center for Clinical Research/Carolinas Pain Institute

Winston-Salem, North Carolina, United States

Site Status

Integrated Pain Solutions

Columbus, Ohio, United States

Site Status

Summa Health System Western Reserve Hospital

Cuyahoga Falls, Ohio, United States

Site Status

Ashland Neurosurgery

Ashland, Oregon, United States

Site Status

Cedar Sinai Medical Center

Ashland, Oregon, United States

Site Status

OAG Interventional Pain Consultants

Portland, Oregon, United States

Site Status

Oregon Anesthesiologist Group Interventional Pain Consultants

Portland, Oregon, United States

Site Status

Einstein Physician Practice, Inc.

Elkins Park, Pennsylvania, United States

Site Status

DNA Advanced Pain Treatment Center

Greensburg, Pennsylvania, United States

Site Status

Houston Pain Associates

Houston, Texas, United States

Site Status

MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Space City Pain Specialists LLP

Webster, Texas, United States

Site Status

Advanced Spine and Pain

Stafford, Virginia, United States

Site Status

The Center for Pain Relief

Charleston, West Virginia, United States

Site Status

The Center of Pain Relief Tri-State

Huntington, West Virginia, United States

Site Status

Anesthesia & Chronic Pain / University of Wisconsin

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

McDowell GC, Saulino MF, Wallace M, Grigsby EJ, Rauck RL, Kim P, Vanhove GF, Ryan R, Huang IZ, Deer T. Effectiveness and Safety of Intrathecal Ziconotide: Final Results of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Med. 2020 Nov 1;21(11):2925-2938. doi: 10.1093/pm/pnaa115.

Reference Type DERIVED
PMID: 32472137 (View on PubMed)

Deer T, Rauck RL, Kim P, Saulino MF, Wallace M, Grigsby EJ, Huang IZ, Mori F, Vanhove GF, McDowell GC 2nd. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2018 Feb;18(2):230-238. doi: 10.1111/papr.12599. Epub 2017 Jul 14.

Reference Type DERIVED
PMID: 28449352 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Zilucoplan for Severe gMG Exacerbations
NCT07215949 NOT_YET_RECRUITING PHASE3
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06672237 ACTIVE_NOT_RECRUITING PHASE3
Early Detection of Neuropathy in ATTRv
NCT05311488 ACTIVE_NOT_RECRUITING